Home Page » RareCyte

News & Events

RareCyte announces the first blood-to-result PD-L1 Circulating Tumor Cell Assay
more →

RareCyte Closes $22M Financing for Global Commercialization and Platform Expansion into Tissue Multiplexing
more →

RareCyte^® expands liquid biopsy offering with the release of a HER2/ER breast cancer CTC Panel Kit.
more →

Highlight

RareCyte expands its world-class liquid biopsy imaging and retrieval platform to support tissue workflows with the new CyteFinder II Instruments.

RarePlex CTC Developer Staining Kit enables custom CTC assay development by providing the ability to add up to two biomarkers-of-interest to the CTC base detection assay.

Pharma Programs

“The RareCyte CTC system has been analytically validated in our CAP/CLIA Laboratory and the validation and acceptance criteria met the needs of the clinical drug study team. In partnership with a global CRO, the CTC workflow is being successfully implemented.”

– Jeff Fill, Senior Director, Diagnostic and Experimental Pathology, Eli Lilly and Company